The FDA has dropped its complaint against fitness tracker company Whoop over its blood pressure monitoring feature, reversing its earlier demand that the tool be disabled.
The reversal marks a significant shift in the agency's regulatory stance toward Whoop's wearable device. The FDA initially took issue with the blood pressure tracking capability, viewing it as a medical device requiring regulatory clearance.
Whoop's blood pressure tool allows users to monitor cardiovascular health through its wrist-worn tracker. The feature had drawn FDA scrutiny over classification and approval pathways, leading to the agency's initial complaint.
The withdrawal suggests either a resolution between Whoop and the FDA regarding the tool's claims and functionality, or a reassessment by the agency of how consumer health tracking features should be regulated.
This outcome could have implications for other wearable manufacturers offering similar health monitoring capabilities. The fitness tracker market continues to expand its health-focused features, creating ongoing questions about where regulators draw lines between consumer wellness tools and medical devices.
Whoop has not yet publicly commented on the FDA's decision.
Semiconductor stocks suffered one of their worst trading days this year, raising questions about the sustainability of equity market gains that have been heavily concentrated in a narrow group of high-performing tech names.
Google's Pixel 10A is getting a $100 price cut at Amazon, dropping from $499 to $399. The discount makes the phone a more compelling value after a lukewarm launch.
Thunderbolt 4 and 5 cables command premium prices despite their USB-C appearance. The difference lies in sophisticated internal engineering required to handle extreme data speeds and power delivery.